Home Blog Page 1895

Innova Therapeutics to Advance Novel Cancer Treatment with Enci Therapeutics Acquisition

By
Advertorial Desk
-

The acquisition of Enci Therapeutics will advance Innova Therapeutics’ lead program, IVT-8086, a humanized monoclonal antibody targeting SFRP2 which is expressed in most solid and hematological cancers.

IVT-8086 is the only cancer therapeutic that targets multiple cell types associated with cancer including the tumor, and multiple components of the tumor microenvironment including endothelial cells, T-cells, and tumor associated macrophages (TAMs) through a common pathway.

MT PLEASANT, S.C., Nov. 25, 2025 /PRNewswire/ — Innova Therapeutics, a biopharmaceutical company, has announced that it has completed the acquisition of Enci Therapeutics. The acquisition includes Enci Therapeutics’ main cancer therapeutic program, IVT-8086. The specific terms of the agreement and financial details regarding the acquisition between Innova Therapeutics and Enci Therapeutics have not been disclosed.

IVT-8086 is a first-in-class, humanized monoclonal antibody (mAb) developed as a cancer therapeutic that targets and antagonizes the Secreted Frizzled-Related Protein 2 (SFRP2) pathway. SFRP2, secreted by tumor and endothelial cells, activates the non-canonical Wnt/Calcium (Ca2+) signaling cascade, a pathway involved in angiogenesis, cell survival, cell growth and proliferation, cell migration and invasion, oncogenesis, and metastasis in cancer. By blocking SFRP2 in preclinical models, IVT-8086 induces multiple antitumor effects, including potent reduction in tumor burden in primary and metastatic tumors, reduced expression of CD38 and PD-1 in tumor-infiltrating lymphocytes (TILs), inhibition of angiogenesis, and increased interferon gamma (IFNγ) in tumor-associated macrophages (TAMs) resulting in macrophage repolarization and subsequent increase in the M1/M2 ratio.

The SFRP2 pathway is highly expressed across numerous solid and hematologic malignancies, positioning IVT-8086 as a potential therapy both as monotherapy and combination with immune checkpoint inhibitors (ICIs) for multiple cancer types. Extensive internal and external validation confirms SFRP2 as a critical molecular target, with expression levels strongly correlating with patient outcomes. In parallel, a diagnostic assay is in development to serve as a potential marker for early cancer detection, a prognostic tool for assessing therapeutic benefit, and an indicator for cancer recurrence risk.

“The acquisition of Enci Therapeutics and IVT-8086 marks a pivotal step for Innova Therapeutics in our commitment to pioneering novel cancer therapies,” said Robert Ryan, Ph.D., Chief Executive Officer of Innova Therapeutics. “IVT-8086’s unique mechanism of action, antagonizing SFRP2 and selectively blocking the non-canonical Wnt/Ca2+ pathway, holds substantial promise for addressing a spectrum of solid tumors, including pediatric osteosarcoma, sarcomas, breast cancer and pancreatic cancer.”

“This cancer treatment platform has the highest potential in my view to change the paradigm of treatment of patients with many types of solid and hematological cancers, resulting in long term survival,” said Dr. Ryan who has worked for more than 30 years in the pharmaceutical industry developing cancer therapies. “Given the extensive global patent protection (including composition of matter) through 2042 and beyond, the commercial value of this platform is high, both as monotherapy and in combination.”

“This strategic acquisition of Enci Therapeutics by Innova Therapeutics, centered around IVT-8086, a monoclonal antibody targeting SFRP2, underscores our dedication to advancing treatment paradigms for refractory cancers,” said Nancy Klauber-DeMore M.D., Co-founder of Enci Therapeutics. “The potential of IVT-8086 to disrupt angiogenesis, tumor cell growth and survival, immune system function, and metastasis represents a significant opportunity to improve outcomes for patients facing these challenging diseases.”

About IVT-8086

IVT-8086 is a first-in-class cancer therapeutic, developed as a humanized monoclonal antibody (mAb) designed to antagonize Secreted Frizzled Related Protein 2 (SFRP2). SFRP2 is a protein expressed at high levels in many solid and hematological malignancies, and its expression is correlated with patient outcomes including overall survival making it an important therapeutic target. IVT-8086 as an SFRP2 antagonist, selectively blocks the non-canonical Wnt/Ca2+ signaling pathway.

About Innova Therapeutics, Inc.

Innova Therapeutics is a Charleston, South Carolina based biotechnology company developing a monoclonal antibody (mAb) platform targeting a protein that is highly expressed in various solid cancers and shown to correlate with patient outcomes, including overall survival. The lead humanized mAb has been selected and is designated as IVT-8086. Innova’s platform technology has broad treatment options across both hematological and solid malignancies. Initially the development of IVT-8086 is initially focused on targeting cancers including pediatric osteosarcoma, sarcomas, breast cancer, multiple myeloma and pancreatic cancer. For further information visit our website at www.innovatherapeutics.com.

About Enci Therapeutics, Inc.

Enci Therapeutics was co-founded by Nancy Klauber-DeMore M.D., FACS, Professor of Surgery Medical University of South Carolina (MUSC) and Dr. Cam Patterson, MD, MBA, Former Provost University of Arkansas Medical Center, to identify and develop monoclonal antibody therapies for cancer.

Forward Looking Statement

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements that involve risks and uncertainties, including: our dependence on third parties for the development, regulatory approval and successful commercialization of our products, the inherent risk of failure in developing product candidates based on new technologies, risks associated with the costs of clinical development efforts, as well as other risks. Actual results may differ materially from those projected. These forward-looking statements represent our judgment as of the date of the release. Innova disclaims any intent or obligation to update these forward-looking statements.

Company Contact

Dr. Robert Ryan

Chief Executive Officer

rryan@innovatherapeutics.com 

(919)-274-0703

CINCOM Launches 2025 Black Friday Sale With Up to 50% Off, Encouraging Consumers to Invest in Self-Care This Season

By
Advertorial Desk
-

NEW YORK, Nov. 25, 2025 /PRNewswire/ — CINCOM, a home-massage and wellness brand dedicated to everyday relaxation, today announced the launch of its 2025 Black Friday–Cyber Monday (BFCM) Sale, offering up to 50% off from November 20 to December 1.

As self-care continues to gain momentum across all age groups, CINCOM’s accessible massage devices provide an easy way for individuals to bring more comfort and recovery into their homes.

A Black Friday Designed for Self-Care

Rather than traditional holiday messaging centered solely on gifting, CINCOM’s 2025 campaign encourages consumers to prioritize their own well-being and daily comfort.

From long workdays and long commutes to workout routines and everyday stress, home-massage tools have become one of the most practical upgrades for personal relaxation. CINCOM’s devices are designed to help users unwind, recharge, and feel better without requiring extra time or complicated routines.

The BFCM sale spans CINCOM’s full lineup, allowing shoppers to invest in meaningful self-care at the brand’s best prices of the year.


Top Categories Featured in the 2025 BFCM Sale

To help shoppers quickly find the right fit for their routines, CINCOM has curated several highlighted collections for the 2025 Black Friday–Cyber Monday event.

Everyday Comfort Under $100
CINCOM’s Under $100 collection is designed for those who want to introduce massage into daily life without a big commitment. From compact hand and leg massagers to easy-to-use entry models, these devices slip seamlessly into workdays, study sessions, and cozy nights in. Ideal for first-time buyers and thoughtful, affordable gifts.

Biggest Savings: 50% OFF
The 50% OFF collection brings together some of CINCOM’s most powerful devices at their best prices of the year. Shoppers can access advanced air-compression leg systems and premium home-massage tools that support relaxation, circulation, and post-activity recovery—now at deeply reduced prices that are rarely seen outside of Black Friday.

Bundle & Save: Build Your Home Spa
For those ready to upgrade more than one area of the body, CINCOM’s Bundle & Save collection makes it easy to build a complete home spa. Thoughtfully paired sets, such as leg and knee massagers for full lower-body relief or hand and neck solutions for desk-bound users, offer better value when purchased together and are ideal for couples, families, or anyone designing a self-care corner at home.

Best-Sellers: Customer Favorites, Proven Relief
Featuring CINCOM’s most trusted leg, hand, and full-body massagers—known for their excellent balance of performance, quality, and price—this Best-Sellers collection is perfect for shoppers who want to go straight to the brand’s most proven solutions for everyday tension, fatigue, and relaxation.


Where to Shop the 2025 BFCM Sale

CINCOM’s Black Friday–Cyber Monday offers will be available across its official channels, giving customers the flexibility to shop where they prefer:

Each channel will feature a selection of CINCOM’s best-selling massage devices, all aligned with the brand’s mission of making at-home wellness more accessible.

A Message From CINCOM

“More people are realizing that self-care isn’t a luxury—it’s a necessity,” said a CINCOM spokesperson.

“Our Black Friday sale gives customers an opportunity to bring meaningful comfort into their homes at the best prices of the year. If there’s a moment to invest in feeling better every day, it’s now.”

A Smart Time for Personal Wellness Upgrades

With strong seasonal discounts and a growing focus on personal well-being, Black Friday has become an ideal moment for consumers looking to improve their daily comfort.

CINCOM’s products—known for their simplicity, warm feel, and consistent performance—are built for real routines, from post-work relaxation to winter comfort and at-home recovery.

Whether shoppers are seeking relief from long workdays, wanting to elevate their self-care rituals, or looking to refresh their home wellness setup, CINCOM’s BFCM lineup provides a practical and immediate-benefit upgrade.

About CINCOM

CINCOM designs approachable home-massage devices that help people relax, recover, and bring more comfort into everyday life. With offerings ranging from air-compression leg systems to hand and neck massagers, CINCOM supports millions of users seeking simple, effective wellness solutions at home.

Baleaf Unveils Black Friday Sale, Spotlighting the Horizon Collection: From City Living to Nature Exploration

By
Advertorial Desk
-

NEW YORK, Nov. 25, 2025 /PRNewswire/ — As the year’s most anticipated shopping moment arrives, Black Friday once again becomes the prime opportunity to refresh an active wardrobe and set new intentions for the year ahead. For many, it is the ideal time to invest in performance-driven essentials while enjoying the deepest savings of the season. Baleaf Black Friday Sale, available now, offers the brand’s biggest discounts of the year.

This year’s Black Friday/Cyber Monday Event, running 11.20–12.1, carries the theme: “Defy the Cold. Define Your Price.”


Alongside the discount period, Baleaf introduces seasonal offers including $15 off $120, $20 off $160, and $50 off $260, giving shoppers flexible ways to build their winter wardrobe.

But amid the overwhelming array of holiday deals, one question remains: Which gear can truly keep up — from high-intensity training to everyday city life? This is where Baleaf delivers its answer.

Introducing the Horizon Collection — “City Is the Start, Beyond Is the Journey.”

At the heart of this year’s spotlight is the Baleaf Horizon Collection, a line that transcends the boundaries between Urban Athleisure, daily comfort, and outdoor-ready performance. The name “Horizon” evokes the idea of broader perspectives and newly opened possibilities — a symbol perfectly aligned with the spirit of looking ahead to a new year.

This season’s Black Friday focus highlights Fleece-Lined essentials, versatile Pants, and all-purpose Long Sleeves — three cold-weather staples that integrate seamlessly with the Horizon Collection’s city-to-nature styling. From insulated fleece interiors to layering-friendly silhouettes, these pieces help wearers stay warm, comfortable, and mobile as temperatures drop.

Crafted for the pace of modern metropolitan life, the Horizon Collection allows wearers to stay energized throughout the day, making movement a natural part of their routine. Its full lineup can be explored, featuring designs that flow with the rhythm of city commutes, spontaneous workouts, and the small but meaningful breaks in between.

As Baleaf articulates: “City is the start, beyond is the journey.”

From Urban Streets to Nature Trails: Designed for Every Path

The Horizon Collection shines through its versatility, enabling effortless transitions between distinctly different yet equally dynamic lifestyles. This year’s Fleece-Lined layers, winter-ready Pants, and base-layer Long Sleeves enhance those transitions, offering both style and insulation for colder climates.


Scene A — Urban Living: Movement Within the City

Picture the early morning glow casting soft light onto quiet streets. A runner steps out, wrapped in the lightweight comfort of Horizon apparel, beginning a city-paced workout that blends seamlessly with the hum of the waking metropolis. Breathable fabrics and fluid silhouettes support each stride with ease.

The run ends, but the day continues. Without a wardrobe change, the same outfit carries the wearer into a nearby café, through a weekend cycling route, or straight to a casual meet-up with friends. This is where style meets performance, and where warmth, layering, and movement become one continuous lifestyle expression.

Scene B — Beyond the City: Exploration Unfolds

From the city’s edge, the path extends outward — into wooded trails, sun-dappled nature routes, or the gentle inclines of a weekend hike. Here, Fleece-Lined leggings or pants matched with insulated vests or Long Sleeves become essential companions for cold-weather exploration. 

The Horizon Collection adapts effortlessly, offering flexibility, breathability, and comfort that feels equally at home on a forest path as on a city sidewalk.

Here, the brand’s belief comes alive:
“Where Comfort Moves, Excellence Flows.” or “Train Here. Go Anywhere.”

See the City. Seek the Horizon. — A Black Friday Call to Action

As consumers prepare for a new year filled with new goals and new horizons, the Horizon Collection stands not just as functional apparel but as an investment in a renewed lifestyle perspective — one that celebrates movement, exploration, and the seamless connection between City and Nature.

And during this year’s Black Friday/Cyber Monday Event (11.20–12.1), shoppers can experience that vision with the biggest savings of the year, plus added seasonal value through fleece-lined layering pieces, winter pants, and all-purpose long sleeves that anchor the modern cold-weather wardrobe.

See the City. Seek the Horizon. 

Shop the Black Friday Sale today to experience the Horizon Collection. Don’t miss the year’s best offers—act now before the sale ends!

BON Announced Next-Gen of Tea Pigment Digestive Health Products and Cooperation Agreement of US$26 Million with Beijing Huahai Keyuan

By
Advertorial Desk
-

XI’AN, China, Nov. 25, 2025 /PRNewswire/ — Bon Natural Life Limited (Nasdaq: BON) (“BON” or the “Company”), a leading bio-ingredient solution provider in the natural, health and personal care industry, today announced a non-exclusive cooperation agreement with Beijing Huahai Keyuan Technology Co. Ltd. (“Huahai Keyuan”) a prominent health products distributor in China. The term of the agreement is 36 months with a total contract value of US$26 million. Pursuant to the agreement, Huahai Keyuan will sell and distribute BON’s second-generation tea pigment-based digestive health products in Greater China.

Tea pigments, a key bioactive complex derived from tea, possess a strong scientific profile across lipid regulation, glycemic control, antioxidant function, and gastrointestinal support. As a next-generation functional tea ingredient, tea pigments represent the most significant innovation in the sector since the commercialization of tea polyphenols. Current market adoption is being driven primarily by two fast-growing segments: digestive wellness and blood-glucose management. With broad applicability and favorable consumer demand trends, tea pigments are positioned as a potential blockbuster ingredient with an anticipated market opportunity exceeding US$1 billion in the coming years.

As a global leading innovator in tea pigment ingredients, BON has identified that targeted biotransformation of tea raw materials can significantly enhance the functional performance of tea pigments. Leveraging this, BON undertook systematic research utilizing its proprietary, optimally selected Eurotium cristatum strain as a fermentation agent. Through a controlled biotransformation process — a precision-optimized fermentation method designed to strengthen functional attributes — BON believes it has achieved a substantial improvement in the digestive health benefits of tea pigments.

Testing demonstrates that the digestive health activity of BON’s latest tea pigment product has increased by more than 200% compared to first-generation formulations, representing a major advancement in product efficacy and competitive positioning.

Hu Yongwei, CEO and Chairman of BON, stated: “Through our strategic partnership with Huahai Keyuan, BON will leverage its competitive strengths and continued innovation in tea pigment technology to accelerate our expansion into the rapidly growing premium digestive health market. This agreement marks the next phase of BON’s strategic development and positions us to drive synergistic growth across the digestive health sector. We also plan to introduce our innovative second-generation tea pigment product portfolio to global markets. BON believes this partnership will support meaningful revenue and earnings growth over time and further enhance long-term shareholder value.”

About Bon Natural Life Limited (“BON”)

BON is a Cayman Islands company engaged in the business of natural, health, and personal care industries. For more information, please visit the Company’s website at http://www.bnlus.com.

For more information, please contact:

Cindy Liu | IR
Email: bonnatural@appchem.cn

Safe Harbor Statement

This press release contains certain statements that may include “forward-looking statements.” All statements other than statements of historical fact included herein are “forward-looking statements.” These forward-looking statements are often identified by the use of forward-looking terminology such as “believes,””expects” or similar expressions, involve known and unknown risks and uncertainties. Although the Company believes that the expectations reflected in such forward-looking statements are reasonable, they do involve assumptions, risks, and uncertainties, and these expectations may prove to be incorrect. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. The Company’s actual results could differ materially from those anticipated in these forward-looking statements as a result of a variety of factors, including those discussed in the Company’s periodic reports that are filed with the Securities and Exchange Commission and available on its website (http://www.sec.gov). All forward-looking statements attributable to the Company or persons acting on its behalf are expressly qualified in their entirety by these factors. Other than as required under the securities laws, the Company does not assume a duty to update these forward-looking statements.

Reolink Black Friday Sale 2025 Is Now Live: Get Up to 55% Off Smart Security Cameras

By
Advertorial Desk
-

LOS ANGELES, Nov. 25, 2025 /PRNewswire/ — Reolink, an innovative leader in smart visual technology for homes and businesses, officially launches its Black Friday sale with its deepest discounts of the year. The event is running now through December 1 on Reolink.com and Amazon.

Reolink Black Friday Deals 2025 are Live
Reolink Black Friday Deals 2025 are Live

Take advantage of exclusive Black Friday deals with significant price reductions on a wide range of security cameras and systems. Enjoy the biggest discount of the sale—55% off on the 4K dual-lens battery camera Argus Track. Also in the spotlight are these impressive cameras, packed with advanced features:

Elite Floodlight WiFi (Save 30%, Now $153.99)

Since its launch in July, the Elite Floodlight WiFi has quickly become a customer favorite, thanks to its 4K UHD resolution and wide 180° panoramic view. Its powerful 3000 lumens floodlights ensure crisp and bright imaging under low-light conditions. Equipped with Reolink’s advanced ReoNeura™ AI technology, the Elite Floodlight WiFi allows users to locate desired video clips within seconds through the Reolink App. Originally $219.99, now it’s $153.99. Customers requiring even sharper image quality and Power-over-Ethernet setup may also consider the 16MP Elite Pro Floodlight PoE as an alternative option.

Argus PT Ultra with Solar Panel (Save 35%, Now $97.99)

The Argus PT Ultra offers an eco-friendly security solution by integrating solar-battery operation with sharp 4K imaging. Its built-in spotlights enable full-color monitoring after dark, and with 355° pan and 140° tilt rotation, the camera eliminates blind spots for full-area surveillance. With intelligent person, vehicle, and pet detection, the camera sends real-time alerts to homeowners wherever they are. Originally $149.99, now it’s $97.99.

Video Doorbell PoE (Save 30%, Now $76.99)

The Reolink Video Doorbell PoE provides 2K+ clarity around the clock, utilizing a unique 4:3 aspect ratio and 180° diagonal view for comprehensive front-door monitoring. It features smart person and package detection to minimize false alerts and offers pre-roll recording to capture key moments—all without a subscription. Users can receive instant push notifications and answer visitor calls directly through the Reolink app. Originally $109.99, now it’s $76.99.

Don’t miss out on Reolink’s amazing Black Friday deals! For a limited time, from now until December 1, enjoy direct price cuts on a wide range of products including battery cameras, PoE cameras, home hubs, and more. Secure your peace of mind today at a premium value.

About Reolink

Reolink offers smart security solutions for homes and businesses, aiming for a seamless security experience with its wide range of products. Serving millions globally, it provides video surveillance and protection, standing out for its commitment to security technology innovation.

World’s Largest Van Gogh Pikachu Card Wall Debuts at Hong Kong Grade10 Festival

By
Advertorial Desk
-

  • Record Turnout Signals City’s Rise as Asia’s Trading Card Hub
  • Event Backed by Virtual Asset Venture MemeStrategy, Entertainment Platform 9GAG

HONG KONG SAR – Media OutReach Newswire – 25 November 2025 – In a city long synonymous with skyscrapers and stock tickers, an unlikely subculture is staking its claim: trading cards. The just-concluded Grade10 Festival, drawing a record 23,000 attendees to Hong Kong’s bustling convention hall in Wan Chai, underscored the territory’s ascent as Asia’s go-to hub for collectors chasing everything from vintage Pokémon rarities to autographed NBA gems. Amid the frenzy, a towering wall of Pikachu cards — each a PSA10 homage to Vincent van Gogh — stole the show, symbolizing how pop culture nostalgia is blending with high-stakes investment in the world’s fastest-growing collectibles market.

The event's centerpiece was a world-first installation: over 400 PSA 10-graded
The event’s centerpiece was a world-first installation: over 400 PSA 10-graded “Pikachu with Grey Felt Hat” cards, stacked into a mosaic valued at around HK$5 million (US$641,000).

The event’s centerpiece was a world-first installation: over 400 PSA 10-graded “Pikachu with Grey Felt Hat” cards, stacked into a mosaic valued at around HK$5 million (US$641,000). Originally released in 2023 as part of a special Pokémon collaboration with the Van Gogh Museum in Amsterdam, the card pays homage to Van Gogh’s Self‑Portrait with Grey Felt Hat, reinterpreted with Pikachu wearing the artist’s signature grey felt hat — a cheeky fusion of 19th century genius and 21st century mascot mania. Four such cards, including two flawless PSA 10s, were given out through on-site participation.

The Grade10 Festival drew a record 23,000 attendees, cementing Hong Kong's status as Asia's go-to hub for collectors.
The Grade10 Festival drew a record 23,000 attendees, cementing Hong Kong’s status as Asia’s go-to hub for collectors.

Hong Kong’s trading card scene is fast becoming a barometer for a regional boom. The global market, valued at US$11.4 billion in 2024, is expected to grow at a CAGR of around 5% through 2033, with Asia-Pacific leading the charge thanks to anime fever and esports crossover. Grading volumes in Hong Kong now rival Chinese Mainland’s entire output, per local retailer HobbyX, while tax-free imports and global connectivity make the city a magnet for deal-makers. “I traveled to Hong Kong for the festival because of its strong market growth and unique position as a bridge between Eastern and Western cultures,” said James Bui of U.S. exhibitor JayBee Collectibles, one of more than 120 international exhibitors at Grade10 — a new high for the territory. “The city’s diverse selection of collectible cards and increasing number of collectors, along with low taxes and convenient transportation, make it an ideal hub for trading cards in Asia.”

More than just cards. This wall of Van Gogh Pikachu cards represents the fusion of pop culture and high-stakes investment in the booming collectibles world.
More than just cards. This wall of Van Gogh Pikachu cards represents the fusion of pop culture and high-stakes investment in the booming collectibles world.

Overseas participation was notable, with 20% of attendees traveling from outside Hong Kong, among them world‑renowned collector Nick Uliano from the United States. Uliano, celebrated for his extensive Michael Jordan collection, specializes in one‑of‑one rarity cards and autographed Buyback cards reissued by publishers. Commenting on the event, he said: “The ‘Grade10 Festival’ is a rare large-scale card event in Asia, and its scale and card diversity are impressive. It brings together top collectors and exhibitors from around the world, and I am delighted to participate in person in this international-level collecting event.”

That sentiment echoed through the festival’s packed aisles, where 60% of the floor space pulsed with anime icons — Pokémon, Dragon Ball, One Piece, Yu-Gi-Oh! — and the rest bowed to sports cards from basketball to soccer.

The festival featured dedicated zones, including areas for grading, gameplay, networking, trading, and the Threads interactive experience. As the first major event jointly supported by publicly listed virtual asset venture MemeStrategy (Stock Code:2440.HK) and online meme platform 9GAG with 200 million users worldwide, the festival introduced the “Threads Wall”, developed by 9GAG in collaboration with Meta’s Threads. The installation proved a major attraction, drawing influencers and generating high levels of on‑site and online engagement.

Beneath the frenzy lies serious economics. Asia’s collectibles surge — from Labubu’s to serialized Pokémon merch — has minted millionaires overnight, with cards like the Illustrator Pikachu fetching six figures. Hong Kong, with its free-port status and proximity to manufacturing powerhouses, is positioning itself as the nexus. As Ray Chan, CEO of event backer MemeStrategy Inc., put it amid the post-festival buzz, “Hong Kong isn’t just hosting; it’s connecting worlds — Japan’s IPs to America’s collectors, culture to capital.”
Hashtag: #MemeStrategy

The issuer is solely responsible for the content of this announcement.

About MemeStrategy

(Stock Code: 2440.HK) is Asia’s first publicly listed digital asset venture, managed by the team behind , a globally acclaimed meme platform with over 200 million users. Leveraging its social media and Web3 expertise, MemeStrategy adopts a people-first approach to strategically invest in three key growth pillars: Artificial Intelligence (AI), Blockchain, and Culture, aiming to bridge the new economy with traditional finance and accelerate the development of decentralized technologies.

About Grade10

was founded in 2023 to unite Hong Kong’s trading card industry and collector community. Over the years, it has grown into the city’s premier platform for card enthusiasts and industry professionals. Grade10 is a division of MemeStrategy (Stock Code: 2440.HK), a publicly listed company founded by the team behind 9GAG, a global social platform with over 200 million users worldwide. Since becoming part of MemeStrategy in September 2025, Grade10 has embarked on a new phase of growth, positioning Hong Kong as the festival’s annual home and establishing Grade10 as the leading touring event for collectible trading cards and related cultural treasures across Asia. In the collecting world, “Grade 10” signifies the highest standard of excellence. True to its name, the Grade10 Card Show brings fresh energy and opportunities to Asia’s collectibles market – offering passionate enthusiasts a vibrant platform to connect, exchange, and showcase their prized collections, while exploring new horizons together with fellow collectors.

Mabwell Announces First-Patient Dosing for Novel CDH17-Targeting ADC 7MW4911

By
Advertorial Desk
-

SHANGHAI, Nov. 25, 2025 /PRNewswire/ — Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the first patient has been dosed in the Phase I/II clinical trial of its independently developed novel CDH17-targeting antibody-drug conjugate (ADC) (R&D code: 7MW4911) for advanced solid tumors.

This Phase I/II clinical trial (CTR20254163) aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of 7MW4911 in patients with advanced solid tumors. Previously, 7MW4911 had received IND clearance from FDA to initiate a Phase I/II clinical trial for advanced colorectal cancer and other advanced gastrointestinal tumors (NCT07216560).

7MW4911 is a novel CDH17-targeting ADC developed by Mabwell based on its proprietary IDDC™ platform. It is composed of a highly specific CDH17 monoclonal antibody capable of efficient internalization into tumor cells, a novel cleavable linker with high plasma stability, and a proprietary DNA topoisomerase I inhibitor payload, MF-6, specifically designed to overcome the multidrug resistance.

Preclinical studies demonstrated that 7MW4911 exhibited potent antitumor activity in CDX/PDX models of various gastrointestinal tumors. In multidrug-resistant models, its antitumor effect was significantly superior to MMAE/DXd-based ADCs, and it was able to reverse tumor progression following treatment with such ADCs, highlighting its advantage in treating resistant tumors. Relevant research findings have been published in the 2025 AACR and the internationally renowned journal Cell Reports Medicine (July 2025).

About Mabwell

Mabwell (688062.SH) is an innovation-driven biopharmaceutical company with capabilities spanning the entire pharmaceutical value chain. The company is committed to providing more effective and accessible therapies to meet global medical needs, with a focus on oncology and aging-related diseases. Mabwell’s mission is “Explore Life, Benefit Health” and its vision is “Innovation, from Ideas to Reality.” For more information, please visit www.mabwell.com/en.

Forward-Looking Statements

This press release contains forward-looking statements including, but not limited to, the potential safety, efficacy, regulatory review or approval and commercial success of our product candidates and those relating to the Company’s product development, clinical studies, clinical and regulatory milestones and timelines, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. “Forward-looking statements” are statements that are not historical facts and involve a number of risks and uncertainties, which may cause actual results to be materially different from any future results expressed or implied in the forward-looking statements. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would,” and similar expressions and the negatives of those terms.

Forward-looking statements are based on the Company’s current expectations and assumptions. Forward-looking statements are subject to a number of risks, uncertainties, and other factors, many of which are beyond the Company’s control, including, but not limited to: environment; politic; economy; society; legislation; our dependence on our product candidates, most of which are still in preclinical or various stages of clinical development; our reliance on third-party vendors, such as contract research organizations and contract manufacturing organizations; the uncertainties inherent in clinical testing; our ability to complete required clinical trials for our product candidates and obtain approval from regulatory authorities for our product candidates; our ability to protect our intellectual property; the loss of any executive officers or key personnel. In case one or more of these risks or uncertainties deteriorate, or any assumptions are incorrect, the actual results may be seriously inconsistent with the stated results.

The Company cautions all the persons not to place undue reliance on any such forward-looking statements, which speaks only as of the date of this press release. The Company disclaims any obligation, except as specifically required by law and the rules of the applicable Stock authority to publicly update or revise any such statements to reflect any change in expectations or in events, conditions, or circumstances on which any such statements may be based, or that may affect the likelihood that actual results will differ from those set forth in the forward-looking statements. All forward-looking descriptions, figures and assumptions in this press release are applicable to this statement.

Dreame Launches AP10 Pet Air Purifier at a Price Lower Than Black Friday

By
Advertorial Desk
-

Advanced Air Purification Engineered for Pet Households

LOS ANGELES, Nov. 25, 2025 /PRNewswire/ — Dreame, a global leader in smart home technology, is proud to announce the launch of its new AP10 Pet Air Purifier, now available at a price lower than Black Friday. The AP10 is designed specifically for pet households, combining advanced filtration technology, thoughtful pet-focused features, and smart home convenience to deliver a healthier and more comfortable living environment.

Dreame AP10 Pet Air Purifier
Dreame AP10 Pet Air Purifier

Pet ownership can often bring unwanted challenges such as hair accumulation, dander, and lingering odors. The Dreame AP10 tackles these problems head-on with powerful, intelligent, and pet-friendly air purification:

  • Visible Hair Collector allows users to see trapped hair for easy monitoring and cleaning
  • Fast Whole-Room Purification refreshes the air in just 7 minutes, ensuring pets and owners breathe clean air quickly
  • Effective Pet Odor Removal with multi-layer filtration to eliminate airborne allergens, dander, and odors
  • Whisper-Quiet Performance keeps pets comfortable while running day and night
  • Bio-Comfort Top and Smart Controls provide effortless operation via app or voice control
  • Detachable Washable Primary Filter reduces filter replacement costs, making maintenance simple and economical

The AP10 is ideal for pet families seeking a reliable solution that balances performance, convenience, and design. Its modern, minimalist aesthetic integrates seamlessly into homes while the advanced technology ensures real, noticeable results in air quality.

Shipping begins November 25, 2025. Dreame continues to lead in smart home innovation, committed to helping pet owners create fresher, cleaner, and safer home environments while offering exceptional value for its customers.

About Dreame Technology

Established in 2017, Dreame Technology is an innovative consumer product company that focuses on smart home cleaning appliances with the vision to empower lives through technology. Follow us on Facebook, Instagram, TikTok and Twitter.

For more information, visit https://www.dreametech.com

 

1...1,8941,8951,896...6,660Page 1,895 of 6,660